NCT05337345View on ClinicalTrials.gov

A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

May 2, 2022

Primary Completion Date

December 15, 2022

Study Completion Date

December 15, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

Cendakimab

Specified Dose on Specified Days

Trial Locations (1)

92801

Anaheim Clinical Trials Llc, Anaheim

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY